Mostrar el registro sencillo del ítem
dc.contributor.author
Alonso, Leonardo Gabriel
dc.contributor.author
Cerutti, Maria Laura
dc.contributor.author
Risso, Marikena Guadalupe
dc.contributor.author
González, Mariángeles
dc.contributor.author
Camporeale, Gabriela
dc.contributor.author
de Prat Gay, Gonzalo
dc.date.available
2017-02-09T18:26:10Z
dc.date.issued
2011
dc.identifier.citation
Alonso, Leonardo Gabriel; Cerutti, Maria Laura; Risso, Marikena Guadalupe; González, Mariángeles; Camporeale, Gabriela; et al.; Desarrollo de una vacuna profilactica de segunda generacion contra el papilomavirus humano; Medicina (buenos Aires); Medicina (buenos Aires); 71; 3; -1-2011; 261-266
dc.identifier.issn
0025-7680
dc.identifier.uri
http://hdl.handle.net/11336/12799
dc.description.abstract
Human papillomaviruses (HPV) are the etiologic agent for cervical cancer (CC), the second cause of cancer death in women worldwide. It is estimated that half a million new cases are diagnosed each year, mostly in developing countries due to the lack of massive programs for early detection of the virus. Recently, two prophylactic vaccines against the main oncogenic HPV types 16 and 18 (responsible for 80% of CC) have been introduced into market. Both of these vaccines, obtained as recombinants, have been shown to be safe and effective; however, their high cost works against its immediate impact in the incidence of HPV infection in developing and low-income countries. There is a need to have in hand second generation, low cost vaccines of massive use that will decrease CC cases in a large extent. With this in mind, we have developed a recombinant expression platform that allows us to obtain virus-like particles (VLPs) to formulate both effective and accessible vaccines against HPV infection.
dc.description.abstract
Human papillomaviruses (HPV) are the etiologic agent for cervical cancer (CC), the second cause of cancer death in women worldwide. It is estimated that half a million new cases are diagnosed each year, mostly in developing countries due to the lack of massive programs for early detection of the virus. Recently, two prophylactic vaccines against the main oncogenic HPV types 16 and 18 (responsible for 80% of CC) have been introduced into market. Both of these vaccines, obtained as recombinants, have been shown to be safe and effective; however, their high cost works against its immediate impact in the incidence of HPV infection in developing and low-income countries. There is a need to have in hand second generation, low cost vaccines of massive use that will decrease CC cases in a large extent. With this in mind, we have developed a recombinant expression platform that allows us to obtain virus-like particles (VLPs) to formulate both effective and accessible vaccines against HPV infection.
dc.format
application/pdf
dc.language.iso
spa
dc.publisher
Medicina (buenos Aires)
dc.rights
info:eu-repo/semantics/openAccess
dc.rights.uri
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.subject
Papillomavirus
dc.subject
Cervical Cancer
dc.subject
Prophylactic Vaccine
dc.subject.classification
Biotecnología relacionada con la Salud
dc.subject.classification
Biotecnología de la Salud
dc.subject.classification
CIENCIAS MÉDICAS Y DE LA SALUD
dc.title
Desarrollo de una vacuna profilactica de segunda generacion contra el papilomavirus humano
dc.title
Development of a second generation prophylactic vaccine against human papillomavirus
dc.type
info:eu-repo/semantics/article
dc.type
info:ar-repo/semantics/artículo
dc.type
info:eu-repo/semantics/publishedVersion
dc.date.updated
2017-02-07T13:52:37Z
dc.journal.volume
71
dc.journal.number
3
dc.journal.pagination
261-266
dc.journal.pais
Argentina
dc.journal.ciudad
Buenos Aires
dc.description.fil
Fil: Alonso, Leonardo Gabriel. Fundación Instituto Leloir; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Investigaciones Bioquimicas de Buenos Aires; Argentina. Xbio S.a; Argentina
dc.description.fil
Fil: Cerutti, Maria Laura. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Investigaciones Bioquimicas de Buenos Aires; Argentina. Fundación Instituto Leloir; Argentina. Xbio S.a; Argentina
dc.description.fil
Fil: Risso, Marikena Guadalupe. Fundación Instituto Leloir; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Investigaciones Bioquimicas de Buenos Aires; Argentina. Xbio S.a; Argentina
dc.description.fil
Fil: González, Mariángeles. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Investigaciones Bioquimicas de Buenos Aires; Argentina. Fundación Instituto Leloir; Argentina. Xbio S.a; Argentina
dc.description.fil
Fil: Camporeale, Gabriela. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Investigaciones Bioquimicas de Buenos Aires; Argentina. Fundación Instituto Leloir; Argentina
dc.description.fil
Fil: de Prat Gay, Gonzalo. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Investigaciones Bioquimicas de Buenos Aires; Argentina. Fundación Instituto Leloir; Argentina
dc.journal.title
Medicina (buenos Aires)
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/http://ref.scielo.org/sp5xnb
Archivos asociados